Comparison between neomycin and lactulose in 173 patients with hepatic encephalopathy - A randomized clinical study

Francesco Orlandi, Umberto Freddara, Maria Teresa Candelaresi, Antonio Morettini, Gino R. Corazza, Aurelio Di Simone, Giorgio Dobrilla, Giorgio Cavallini

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

A randomized study was performed in order to compare the course of hepatic encephalopathy in patients treated with neomycin plus magnesium sulfate or with lactulose. Admission criteria were: morphological diagnosis of cirrhosis and absence of comorbidity, of contraindications to drugs, or of previous treatments which could influence the outcome. The treatment groups were similar in terms of clinical characteristics, fatalities, recovery rate from grade 1 encephalopathy, and disappearance rate of neuropsychiatric signs. Transitions from severe to grade 1 or 0 encephalopathy showed a 0.17 (NS) difference in favor of neomycin. Early therapy and evidence of precipitating factors showed a favorable prognostic significance. Ascites, hyperbilirubinemia, poor nutritional state, and hypoprothrombinemia showed bad prognostic significance. This is the first large-scale investigation on hepatic encephalopathy. It demonstrated a similar effectiveness of the two drugs in grade 1 encephalopathy and provides a basis for drug selection in the current management of the syndrome.

Original languageEnglish
Pages (from-to)498-506
Number of pages9
JournalDigestive Diseases and Sciences
Volume26
Issue number6
DOIs
Publication statusPublished - Jun 1981

Fingerprint

Lactulose
Neomycin
Hepatic Encephalopathy
Brain Diseases
Hypoprothrombinemias
Pharmaceutical Preparations
Precipitating Factors
Magnesium Sulfate
Hyperbilirubinemia
Secondary Prevention
Ascites
Comorbidity
Fibrosis
Therapeutics
Clinical Studies

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Comparison between neomycin and lactulose in 173 patients with hepatic encephalopathy - A randomized clinical study. / Orlandi, Francesco; Freddara, Umberto; Candelaresi, Maria Teresa; Morettini, Antonio; Corazza, Gino R.; Di Simone, Aurelio; Dobrilla, Giorgio; Cavallini, Giorgio.

In: Digestive Diseases and Sciences, Vol. 26, No. 6, 06.1981, p. 498-506.

Research output: Contribution to journalArticle

Orlandi, F, Freddara, U, Candelaresi, MT, Morettini, A, Corazza, GR, Di Simone, A, Dobrilla, G & Cavallini, G 1981, 'Comparison between neomycin and lactulose in 173 patients with hepatic encephalopathy - A randomized clinical study', Digestive Diseases and Sciences, vol. 26, no. 6, pp. 498-506. https://doi.org/10.1007/BF01308097
Orlandi, Francesco ; Freddara, Umberto ; Candelaresi, Maria Teresa ; Morettini, Antonio ; Corazza, Gino R. ; Di Simone, Aurelio ; Dobrilla, Giorgio ; Cavallini, Giorgio. / Comparison between neomycin and lactulose in 173 patients with hepatic encephalopathy - A randomized clinical study. In: Digestive Diseases and Sciences. 1981 ; Vol. 26, No. 6. pp. 498-506.
@article{bcce3cb4952e433e89f6744fc14d4faf,
title = "Comparison between neomycin and lactulose in 173 patients with hepatic encephalopathy - A randomized clinical study",
abstract = "A randomized study was performed in order to compare the course of hepatic encephalopathy in patients treated with neomycin plus magnesium sulfate or with lactulose. Admission criteria were: morphological diagnosis of cirrhosis and absence of comorbidity, of contraindications to drugs, or of previous treatments which could influence the outcome. The treatment groups were similar in terms of clinical characteristics, fatalities, recovery rate from grade 1 encephalopathy, and disappearance rate of neuropsychiatric signs. Transitions from severe to grade 1 or 0 encephalopathy showed a 0.17 (NS) difference in favor of neomycin. Early therapy and evidence of precipitating factors showed a favorable prognostic significance. Ascites, hyperbilirubinemia, poor nutritional state, and hypoprothrombinemia showed bad prognostic significance. This is the first large-scale investigation on hepatic encephalopathy. It demonstrated a similar effectiveness of the two drugs in grade 1 encephalopathy and provides a basis for drug selection in the current management of the syndrome.",
author = "Francesco Orlandi and Umberto Freddara and Candelaresi, {Maria Teresa} and Antonio Morettini and Corazza, {Gino R.} and {Di Simone}, Aurelio and Giorgio Dobrilla and Giorgio Cavallini",
year = "1981",
month = "6",
doi = "10.1007/BF01308097",
language = "English",
volume = "26",
pages = "498--506",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Springer New York",
number = "6",

}

TY - JOUR

T1 - Comparison between neomycin and lactulose in 173 patients with hepatic encephalopathy - A randomized clinical study

AU - Orlandi, Francesco

AU - Freddara, Umberto

AU - Candelaresi, Maria Teresa

AU - Morettini, Antonio

AU - Corazza, Gino R.

AU - Di Simone, Aurelio

AU - Dobrilla, Giorgio

AU - Cavallini, Giorgio

PY - 1981/6

Y1 - 1981/6

N2 - A randomized study was performed in order to compare the course of hepatic encephalopathy in patients treated with neomycin plus magnesium sulfate or with lactulose. Admission criteria were: morphological diagnosis of cirrhosis and absence of comorbidity, of contraindications to drugs, or of previous treatments which could influence the outcome. The treatment groups were similar in terms of clinical characteristics, fatalities, recovery rate from grade 1 encephalopathy, and disappearance rate of neuropsychiatric signs. Transitions from severe to grade 1 or 0 encephalopathy showed a 0.17 (NS) difference in favor of neomycin. Early therapy and evidence of precipitating factors showed a favorable prognostic significance. Ascites, hyperbilirubinemia, poor nutritional state, and hypoprothrombinemia showed bad prognostic significance. This is the first large-scale investigation on hepatic encephalopathy. It demonstrated a similar effectiveness of the two drugs in grade 1 encephalopathy and provides a basis for drug selection in the current management of the syndrome.

AB - A randomized study was performed in order to compare the course of hepatic encephalopathy in patients treated with neomycin plus magnesium sulfate or with lactulose. Admission criteria were: morphological diagnosis of cirrhosis and absence of comorbidity, of contraindications to drugs, or of previous treatments which could influence the outcome. The treatment groups were similar in terms of clinical characteristics, fatalities, recovery rate from grade 1 encephalopathy, and disappearance rate of neuropsychiatric signs. Transitions from severe to grade 1 or 0 encephalopathy showed a 0.17 (NS) difference in favor of neomycin. Early therapy and evidence of precipitating factors showed a favorable prognostic significance. Ascites, hyperbilirubinemia, poor nutritional state, and hypoprothrombinemia showed bad prognostic significance. This is the first large-scale investigation on hepatic encephalopathy. It demonstrated a similar effectiveness of the two drugs in grade 1 encephalopathy and provides a basis for drug selection in the current management of the syndrome.

UR - http://www.scopus.com/inward/record.url?scp=0019465359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019465359&partnerID=8YFLogxK

U2 - 10.1007/BF01308097

DO - 10.1007/BF01308097

M3 - Article

VL - 26

SP - 498

EP - 506

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 6

ER -